These findings supported the inclusion of the TRIUMPH-3 cardiovascular outcomes trial in the Phase 3 program
Although diabetes is widely accepted as one of the major risk factors for cardiovascular disease, the cardiovascular safety of antidiabetic drugs has been questioned due to the finding that intensive glycemic control by antidiabetic medications may result in an unexpected increase in cardiovascular death under certain circumstances [6]
(PubMed) van der Put NM, van den Heuvel LP, Steegers-Theunissen RP, et al
Patients of all sizes The effects of GLP-1 injections are effective and safe for patients of all ages, BMIs, races, and ethnicities
At first, they get 1,000 mcg injections every week for 4-8 weeks
Research suggests DSIP plays a role in modulating neurotransmitter activity, stress hormones, and neuroendocrine pathways